Adjuvant Therapy in Gastric Cancer: What is the Optimal Approach?

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2013 Jan 29

PMID 23355076

Citations 3

Authors

Takashi Taketa

Kazuki Sudo

Roopma Wadhawa

Mariela M Blum

Jaffer A Ajani

Affiliations

Soon will be listed here.

Abstract

Gastric cancer confers a poor prognosis even when diagnosed as localized disease. Multimodality therapy improves the cure rate of patients with localized cancer. However, adjunctive therapeutic approaches differ in different regions of the world. This review focuses on the current standards and unresolved issues based on updated literature on therapy for localized gastric cancer. In the USA, the Intergroup 0116 trial established the use of postoperative chemoradiotherapy as a standard for patients who have surgery first for treatment of gastric cancer. In Europe, the MAGIC trial investigating perioperative chemotherapy demonstrated a survival benefit for gastric cancer patients. Finally, in Asia, the ACTS-GC and CLASSIC trials investigating postoperative chemotherapy established this as the standard of care after primary surgery that included D2 dissection. It is clear, however, that surgery alone is insufficient to achieve the highest possible cure rates.

Citing Articles

Evaluation of prognostic factors and survival results in gastric carcinoma: single center experience from Northeast Turkey.

Canyilmaz E, Soydemir G, Serdar L, Hanedan Uslu G, Sahbaz A, Colak F Int J Clin Exp Med. 2014; 7(9):2656-66.

PMID: 25356123 PMC: 4211773.

Laparoscopic resection of synchronous gastric cancer and primary small intestinal lymphoma: a case report.

Chen D, Pan Y, Yan J, Mou Y World J Gastroenterol. 2014; 20(20):6353-6.

PMID: 24876758 PMC: 4033475. DOI: 10.3748/wjg.v20.i20.6353.

miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.

Cao W, Yang W, Fan R, Li H, Jiang J, Geng M Tumour Biol. 2013; 35(2):1287-95.

PMID: 24068565 DOI: 10.1007/s13277-013-1171-7.

References

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

Kim J, Kim M, Kim T, Lee S, Kim D, Im S . Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer. 2009; 100(5):732-8. PMC: 2653762. DOI: 10.1038/sj.bjc.6604936. View

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

Kim S, Lim D, Lee J, Kang W, Macdonald J, Park C . An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005; 63(5):1279-85. DOI: 10.1016/j.ijrobp.2005.05.005. View

Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S . Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18(21):5992-6000. DOI: 10.1158/1078-0432.CCR-12-1318. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Bouche O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G . Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005; 16(9):1488-97. DOI: 10.1093/annonc/mdi270. View

Ajani J, Mansfield P, Janjan N, Morris J, Pisters P, Lynch P . Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004; 22(14):2774-80. DOI: 10.1200/JCO.2004.01.015. View

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T . Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29(33):4387-93. DOI: 10.1200/JCO.2011.36.5908. View

10.

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

11.

Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S . Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008; 100(6):388-98. DOI: 10.1093/jnci/djn054. View

12.

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

13.

Zhang Z, Gu X, Yin W, Huang G, Zhang D, Zhang R . Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys. 1998; 42(5):929-34. DOI: 10.1016/s0360-3016(98)00280-6. View

14.

Dikken J, van Sandick J, Swellengrebel H, Lind P, Putter H, Jansen E . Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer. 2011; 11:329. PMC: 3175221. DOI: 10.1186/1471-2407-11-329. View

15.

Howlader N, Ries L, Stinchcomb D, Edwards B . The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst. 2009; 101(7):533-6. PMC: 2720708. DOI: 10.1093/jnci/djn517. View

16.

Ajani J, Winter K, Okawara G, Donohue J, Pisters P, Crane C . Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006; 24(24):3953-8. DOI: 10.1200/JCO.2006.06.4840. View

17.

Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y . Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003; 21(12):2282-7. DOI: 10.1200/JCO.2003.06.103. View

18.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

19.

MOERTEL C, CHILDS D, OFallon J, HOLBROOK M, SCHUTT A, Reitemeier R . Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984; 2(11):1249-54. DOI: 10.1200/JCO.1984.2.11.1249. View

20.

Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K . Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999; 354(9175):273-7. DOI: 10.1016/s0140-6736(99)01048-x. View